Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL F JARDULA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1346222510
CMS profile
196394
Location
PALM SPRINGS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,498.95

76 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,785.55 24
Food and Beverage $1,648.86 50
Education $64.54 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL F JARDULA

NPI 1346222510 · CMS profile ID 196394

Allopathic & Osteopathic Physicians / Internal Medicine

PALM SPRINGS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346222510?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL F JARDULA, NPI 1346222510, CMS profile ID 196394. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346222510?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MICHAEL F JARDULA, NPI 1346222510, CMS profile ID 196394. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346222510?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MICHAEL F JARDULA, NPI 1346222510, CMS profile ID 196394, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1346222510?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

76 matching records · $3,498.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 76 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–76 of 76.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $14.1206/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135223857 CMS
Eli Lilly and Company $32.9606/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135223860 CMS
Eli Lilly and Company $51.0106/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135234879 CMS
Merck Sharp & Dohme LLC $27.3806/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141874367 CMS
ABBVIE INC. $13.3806/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103988832 CMS
Bayer Healthcare Pharmaceuticals Inc. $21.0506/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086156534 CMS
Novo Nordisk Inc $32.2705/31/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096690653 CMS
Novo Nordisk Inc $32.2705/31/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096906505 CMS
Phathom Pharmaceuticals, Inc. $20.7505/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151076646 CMS
ViiV Healthcare Company $21.4605/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112805157 CMS
ABBVIE INC. $20.8005/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103988830 CMS
AstraZeneca Pharmaceuticals LP $24.7104/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104434135 CMS
ViiV Healthcare Company $27.1804/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112826959 CMS
Amgen Inc. $26.8004/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117286675 CMS
Lundbeck LLC $25.7704/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145928870 CMS
Xeris Pharmaceuticals, Inc. $21.6604/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144605872 CMS
ViiV Healthcare Company $20.8504/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112720564 CMS
Phathom Pharmaceuticals, Inc. $18.3403/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151076644 CMS
Amgen Inc. $24.9503/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117286673 CMS
IDORSIA PHARMACEUTICALS US INC $19.1702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146754645 CMS
Merck Sharp & Dohme LLC $20.3002/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141710271 CMS
ViiV Healthcare Company $0.8202/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112708602 CMS
ViiV Healthcare Company $27.0702/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112791610 CMS
ViiV Healthcare Company $125.0002/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112799326 CMS
AstraZeneca Pharmaceuticals LP $14.9201/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104639783 CMS
ViiV Healthcare Company $120.5701/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112703448 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,467.75 75
PY2020 $244.24 15
PY2021 $590.89 27
PY2022 $796.69 42
PY2023 $2,250.29 44
PY2024 $3,498.95 76
PY2025 $390.66 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $95.01 1
PY2025 Principal investigator $635,089.61 41
PY2024 Recipient $45,872.00 3
PY2024 Principal investigator $636,182.42 125
PY2023 Principal investigator $730,938.00 182
PY2022 Recipient $3,840.83 15
PY2022 Principal investigator $389,446.02 658
PY2021 Principal investigator $632,694.80 1,598
PY2020 Recipient $1,329.63 1
PY2020 Principal investigator $555,691.54 641
PY2019 Recipient $1,110.16 11
PY2019 Principal investigator $664,483.84 168

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Abbott Laboratories $712.50 12/16/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248162058
Principal investigator 1 Janssen Research & Development, LLC $3,604.00 12/12/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175080
Principal investigator 1 Eli Lilly and Company $1,020.92 11/19/2025 Non-covered Recipient Entity
DESERT MED GROUP DBA DESERT OASIS HLTHCARE
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187882354
Principal investigator 1 Janssen Research & Development, LLC $6,832.00 11/19/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175087
Principal investigator 1 Abbott Laboratories $997.50 11/07/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248162780
Principal investigator 1 Janssen Research & Development, LLC $10,156.00 11/07/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175128
Principal investigator 1 Janssen Research & Development, LLC $800.00 11/03/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175171
Principal investigator 1 Eli Lilly and Company $998.95 10/28/2025 Non-covered Recipient Entity
DESERT MED GROUP DBA DESERT OASIS HLTHCARE
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187880475
Principal investigator 1 Abbott Laboratories $12.00 10/15/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248162122
Principal investigator 1 Abbott Laboratories $35.00 10/15/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248162124
Principal investigator 1 Abbott Laboratories $1,140.00 10/06/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248162120
Principal investigator 1 Janssen Research & Development, LLC $7,611.00 09/19/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175102
Principal investigator 1 Abbott Laboratories $4,393.00 09/03/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248157674
Principal investigator 1 Abbott Laboratories $1,140.00 08/28/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248157672
Principal investigator 1 Janssen Research & Development, LLC $8,123.00 08/25/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175165
Principal investigator 1 Abbott Laboratories $855.00 08/12/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248157670
Principal investigator 1 Janssen Research & Development, LLC $14,856.00 07/23/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175072
Principal investigator 1 Abbott Laboratories $1,888.99 07/07/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248157668
Principal investigator 1 Janssen Research & Development, LLC $4,005.00 06/23/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175179
Principal investigator 1 Janssen Research & Development, LLC $5,751.00 06/20/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175155
Recipient Eli Lilly and Company $95.01 05/30/2025 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187872847
Principal investigator 1 Abbott Laboratories $2,416.15 05/21/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153896
Principal investigator 1 Abbott Laboratories $1,425.00 05/21/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153898
Principal investigator 1 Abbott Laboratories $35.00 05/21/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153900
Principal investigator 1 Abbott Laboratories $12.00 05/21/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153902
Principal investigator 1 Abbott Laboratories $20.00 05/21/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153904
Principal investigator 1 Abbott Laboratories $90.00 05/21/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153906
Principal investigator 1 Abbott Laboratories $18.99 05/21/2025 Non-covered Recipient Entity
Desert Oasis Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153908
Principal investigator 1 Janssen Research & Development, LLC $6,443.00 05/21/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175119
Principal investigator 1 Janssen Research & Development, LLC $11,427.00 04/23/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175136
Principal investigator 1 Novo Nordisk AS $26,750.68 03/31/2025 Non-covered Recipient Entity
DESERT OASIS HEALTHCARE
EX9924-4473 No dispute reported 06/30/2026 1213828788
Principal investigator 1 Janssen Research & Development, LLC $7,230.00 03/21/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175146
Principal investigator 1 Novo Nordisk AS $1,000.00 02/21/2025 Non-covered Recipient Entity
DESERT OASIS HEALTHCARE
EX9924-4473 No dispute reported 06/30/2026 1213770122
Principal investigator 1 Janssen Research & Development, LLC $11,720.00 02/19/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175094
Principal investigator 1 Eli Lilly and Company $1,004.30 02/07/2025 Non-covered Recipient Entity
DESERT MED GROUP DBA DESERT OASIS HLTHCARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187880781
Principal investigator 1 Eli Lilly and Company $34,184.00 02/04/2025 Non-covered Recipient Entity
DESERT MED GROUP DBA DESERT OASIS HLTHCARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187882482
Principal investigator 1 Amgen Inc. $32,979.20 01/29/2025 Non-covered Recipient Entity
DESERT MEDICAL GROUP INC DBA DESERT OASIS HEALTHCARE MED GRP
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246640753
Principal investigator 1 Eli Lilly and Company $4,662.43 01/27/2025 Non-covered Recipient Entity
DESERT MED GROUP DBA DESERT OASIS HLTHCARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187880473
Principal investigator 1 Janssen Research & Development, LLC $13,641.00 01/22/2025 Non-covered Recipient Entity
Desert Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175175112
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,600.00 01/08/2025 Non-covered Recipient Entity
DESERT OASIS HEALTHCARE
A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi No dispute reported 06/30/2026 1185544379
Principal investigator 1 Eli Lilly and Company $148,020.00 01/07/2025 Non-covered Recipient Entity
DESERT MED GROUP DBA DESERT OASIS HLTHCARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187880471
Principal investigator 1 Eli Lilly and Company $248,479.00 01/07/2025 Non-covered Recipient Entity
DESERT MED GROUP DBA DESERT OASIS HLTHCARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187880783